NCT00315055View on ClinicalTrials.gov

Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule

PHASE3CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

February 29, 2008

Conditions
Hepatitis BPolioDiphtheriaPertussis
Interventions
BIOLOGICAL

DTaP-IPV-HB-PRP~T vaccine

0.5 mL, Intramuscular (IM)

BIOLOGICAL

DTaP-IPV//PRP~T combined

0.5 mL, IM

BIOLOGICAL

Hepatitis B vaccine

0.5 mL, IM

Trial Locations (1)

Unknown

Ankara

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00315055 - Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule | Biotech Hunter | Biotech Hunter